8 results
Primary objectives:To determine the objective tumor response (CR + PR) after 3 weeks of erlotinibSecondary objectives: To describe predictive markers for response:- radiological response (FDG-PET/CT)- EGFR mutations (HER1)To determine (diseasefree)…
Primary objective: Efficacy of erlotinib plus bevacizumab subsequent to the combination of carboplatin, paclitaxel and bevacizumab as determined by the maximum achieved disease control rate (DCR, complete response, partial response, or stable…
Primary:•Efficacy of combination of erlotinib and sorafenib as determined by the rate of no progression at 6 weeks.•Determination of the impact of concomitant administration of sorafenib on the pharmacokinetics (PK) of erlotinibSecondary:•Efficacy…
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
Subcutaneous stimulation as add on therapy to spinal cord stimulaion to treat low back pain in FBSS.
The aim of the randomized controlled study is to evaluate the effect of SubQ on low back pain in FBSS patients for whom SCS gives an inadequate back pain relief. We hypothesize that SubQ in addition to SCS in FBSS patients with leg and low back pain…
The purpose of this clinical trial is to test whether treatment of patients with NSCLC with erlotinib plus sunitinib is better than treatment with erlotinib plus placebo. All patients enrolling in this study will receive treatment with erlotinib.
The primary objective of this study is to compare the Overall Survival (OS) of first-linemaintenance therapy with erlotinib versus erlotinib administered at the time of diseaseprogression in patients with histologically documented, advanced or…
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.